Diabetes drug approvals under fire

Health policy experts have taken regulatory bodies to task for the ease with which they approve drugs for type 2 diabetes.

Their analysis published in the BMJ says agencies such as the FDA and EMA routinely approve drugs on the basis of small, highly selective placebo-controlled studies with short-term surrogate endpoints, offering no evidence for long-term harms and benefits.

The researchers,